Rescue FK506 early conversion for refractory rejection after pediatric liver transplantation: Experience in 20 children

P. Reggiani, B. Gridelli, M. Colledan, G. Rossi, A. Lucianetti, D. Galmarini, L. R. Fassati

Research output: Contribution to journalArticle

Abstract

Tacrolimus (FK506) is an effective and relatively safe novel immunosuppressant able to revert refractory rejection after pediatric liver transplantation (LTx). Between April 1993 and October 1996, 20 pediatric patients were converted to tacrolimus for biopsy-proven, steroid-resistant liver rejection. The mean follow-up was 18 months. The median time from LTx to switch was 20 days. Tacrolimus was administered per os at a mean dosage of 0.23 mg/kg per day to maintain median blood levels of 10.8 ng/ml at 1 week and 9.2 ng/ml at 1 year from the switch. Of the 20 patients, 15 are alive and they all recovered from rejection without the need of OKT3 after conversion. The major causes of death were: one multiorgan failure, two infections (cytomegalovirus Aspergillus), one bowel perforation, and one posttransplant lymphoproliferative disease. One patient experienced late side effects and was reconverted to cyclosporine when she was already rescued from hepatic allograft rejection. The results confirm that an earlier conversion to tacrolimus should be recommended after pediatric liver transplantation in order to revert hepatic allograft rejection with the best safety profile.

Original languageEnglish
JournalTransplant International
Volume11
Issue numberSUPPL. 1
Publication statusPublished - 1998

Fingerprint

Tacrolimus
Liver Transplantation
Pediatrics
Allografts
Liver
Muromonab-CD3
Cytomegalovirus Infections
Aspergillus
Immunosuppressive Agents
Cyclosporine
Cause of Death
Steroids
Biopsy
Safety

Keywords

  • Child
  • Human
  • Liver transplantation
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation

Cite this

Rescue FK506 early conversion for refractory rejection after pediatric liver transplantation : Experience in 20 children. / Reggiani, P.; Gridelli, B.; Colledan, M.; Rossi, G.; Lucianetti, A.; Galmarini, D.; Fassati, L. R.

In: Transplant International, Vol. 11, No. SUPPL. 1, 1998.

Research output: Contribution to journalArticle

Reggiani, P. ; Gridelli, B. ; Colledan, M. ; Rossi, G. ; Lucianetti, A. ; Galmarini, D. ; Fassati, L. R. / Rescue FK506 early conversion for refractory rejection after pediatric liver transplantation : Experience in 20 children. In: Transplant International. 1998 ; Vol. 11, No. SUPPL. 1.
@article{5050ae259da64c8e8353a4548ac3826c,
title = "Rescue FK506 early conversion for refractory rejection after pediatric liver transplantation: Experience in 20 children",
abstract = "Tacrolimus (FK506) is an effective and relatively safe novel immunosuppressant able to revert refractory rejection after pediatric liver transplantation (LTx). Between April 1993 and October 1996, 20 pediatric patients were converted to tacrolimus for biopsy-proven, steroid-resistant liver rejection. The mean follow-up was 18 months. The median time from LTx to switch was 20 days. Tacrolimus was administered per os at a mean dosage of 0.23 mg/kg per day to maintain median blood levels of 10.8 ng/ml at 1 week and 9.2 ng/ml at 1 year from the switch. Of the 20 patients, 15 are alive and they all recovered from rejection without the need of OKT3 after conversion. The major causes of death were: one multiorgan failure, two infections (cytomegalovirus Aspergillus), one bowel perforation, and one posttransplant lymphoproliferative disease. One patient experienced late side effects and was reconverted to cyclosporine when she was already rescued from hepatic allograft rejection. The results confirm that an earlier conversion to tacrolimus should be recommended after pediatric liver transplantation in order to revert hepatic allograft rejection with the best safety profile.",
keywords = "Child, Human, Liver transplantation, Tacrolimus",
author = "P. Reggiani and B. Gridelli and M. Colledan and G. Rossi and A. Lucianetti and D. Galmarini and Fassati, {L. R.}",
year = "1998",
language = "English",
volume = "11",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Blackwell Publishing Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Rescue FK506 early conversion for refractory rejection after pediatric liver transplantation

T2 - Experience in 20 children

AU - Reggiani, P.

AU - Gridelli, B.

AU - Colledan, M.

AU - Rossi, G.

AU - Lucianetti, A.

AU - Galmarini, D.

AU - Fassati, L. R.

PY - 1998

Y1 - 1998

N2 - Tacrolimus (FK506) is an effective and relatively safe novel immunosuppressant able to revert refractory rejection after pediatric liver transplantation (LTx). Between April 1993 and October 1996, 20 pediatric patients were converted to tacrolimus for biopsy-proven, steroid-resistant liver rejection. The mean follow-up was 18 months. The median time from LTx to switch was 20 days. Tacrolimus was administered per os at a mean dosage of 0.23 mg/kg per day to maintain median blood levels of 10.8 ng/ml at 1 week and 9.2 ng/ml at 1 year from the switch. Of the 20 patients, 15 are alive and they all recovered from rejection without the need of OKT3 after conversion. The major causes of death were: one multiorgan failure, two infections (cytomegalovirus Aspergillus), one bowel perforation, and one posttransplant lymphoproliferative disease. One patient experienced late side effects and was reconverted to cyclosporine when she was already rescued from hepatic allograft rejection. The results confirm that an earlier conversion to tacrolimus should be recommended after pediatric liver transplantation in order to revert hepatic allograft rejection with the best safety profile.

AB - Tacrolimus (FK506) is an effective and relatively safe novel immunosuppressant able to revert refractory rejection after pediatric liver transplantation (LTx). Between April 1993 and October 1996, 20 pediatric patients were converted to tacrolimus for biopsy-proven, steroid-resistant liver rejection. The mean follow-up was 18 months. The median time from LTx to switch was 20 days. Tacrolimus was administered per os at a mean dosage of 0.23 mg/kg per day to maintain median blood levels of 10.8 ng/ml at 1 week and 9.2 ng/ml at 1 year from the switch. Of the 20 patients, 15 are alive and they all recovered from rejection without the need of OKT3 after conversion. The major causes of death were: one multiorgan failure, two infections (cytomegalovirus Aspergillus), one bowel perforation, and one posttransplant lymphoproliferative disease. One patient experienced late side effects and was reconverted to cyclosporine when she was already rescued from hepatic allograft rejection. The results confirm that an earlier conversion to tacrolimus should be recommended after pediatric liver transplantation in order to revert hepatic allograft rejection with the best safety profile.

KW - Child

KW - Human

KW - Liver transplantation

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=0031609888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031609888&partnerID=8YFLogxK

M3 - Article

C2 - 9664995

AN - SCOPUS:0031609888

VL - 11

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - SUPPL. 1

ER -